---
title: "Kenvue: An Intriguing Turnaround"
date: "2025-02-10 08:03:31"
summary: "skhoward  Kenvue (NYSE:KVUE) has disappointed again. The former consumer health business of Johnson &amp; Johnson (JNJ) went public 21 months ago, and its performance since then clearly has fallen short. Kenvue cut guidance in both 2023 and 2024, and"
categories:
  - "seekalpha_articles"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha_articles"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458549551/image_458549551.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

![Sealed Bottle of Extra Strength Tylenol Caplets with Box](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458549551/image_458549551.jpg?io=getty-c-w750) 



skhoward





Kenvue (NYSE:[KVUE](https://seekingalpha.com/symbol/KVUE "Kenvue Inc.")) has disappointed again. The former consumer health business of Johnson & Johnson ([JNJ](https://seekingalpha.com/symbol/JNJ "Johnson & Johnson")) went public 21 months ago, and its performance since then clearly has fallen short. Kenvue cut guidance in both 2023 and 2024, and

[seekalpha_articles](https://seekingalpha.com/article/4756517-kenvue-an-intriguing-turnaround)
